Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(lesinurad)
119 results
  • Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). [Journal Article]
    Expert Opin Ther Pat 2019; :1-9Dong Y, Zhao T, … Zhan P
  • Introduction: Human urate transporter 1 (URAT1), which is an influx transporter protein, is located at the apical surface of renal tubular cells and presumed to be the major transporter responsible for the reabsorption of urate from blood. About 90% of patients develop hyperuricemia due to insufficient urate excretion; thus, it is important to develop URAT1 inhibitors that could enhance renal urat…
  • Management of complex gout in clinical practice: Update on therapeutic approaches. [Review]
    Best Pract Res Clin Rheumatol 2018; 32(6):813-834Narang RK, Dalbeth N
  • Increasing therapeutic options are available for gout management. Anti-inflammatory agents are used in the acute management of gout flares, and interleukin-1 inhibitors are effective for those unable to take conventional anti-inflammatory treatments. Lowering of serum urate remains the cornerstone of effective long-term management. Allopurinol is the first-line urate-lowering therapy, and a gradu…
  • Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. [Journal Article]
    Clin Rheumatol 2019Presa M, Pérez-Ruiz F, Oyagüez I
  • CONCLUSIONS: Lesinurad plus allopurinol therapy compared with febuxostat seems an effective option for the management of hyperuricemia in patients who did not reach serum urate target to previous allopurinol monotherapy, associated to cost-savings for the Spanish Health System. Key Points • Lesinurad, in combination with allopurinol, has been recently authorized as second-line treatment of hyperuricemia in gout patients. • Lesinurad plus allopurinol provided higher effectiveness in terms of quality-adjusted-life-years (14.79) than febuxostat (14.69). • Lesinurad plus allopurinol resulted less costly (total cost/per patient) compared with febuxostat. • Lesinurad plus allopurinol resulted a dominant option compared with febuxostat.
  • Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. [Journal Article]
    J Pharmacol Exp Ther 2019; 371(1):162-170Taniguchi T, Ashizawa N, … Iwanaga T
  • The effect of dotinurad [(3,5-dichloro-4-hydroxyphenyl)(1,1-dioxo-1,2-dihydro-3H-1λ 6-1,3-benzothiazol-3-yl)methanone] was compared with that of commercially available uricosuric agents-namely, benzbromarone, lesinurad, and probenecid. Its effect on urate secretion transporters was evaluated using probe substrates for respective transporters. Dotinurad, benzbromarone, lesinurad, and probenecid in…
  • Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. [Review]
    Drugs Context 2019; 8:212581Pérez-Ruiz F, Jansen T, … Richette P
  • The aim of this review is to present current evidence about the efficacy and safety of lesinurad in combination with xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricemia in patients with gout. Gout is the most common inflammatory form of arthritis. It is caused by an elevated concentration of serum uric acid (UA) that leads to the formation of monosodium urate crystals in joints a…
  • Safety and tolerability of available urate-lowering drugs: a critical review. [Review]
    Expert Opin Drug Saf 2019; 18(4):261-271Strilchuk L, Fogacci F, Cicero AF
  • Urate-lowering therapy (ULT) is the cornerstone of gout management, which is a widespread chronic illness characterized by hyperuricemia, arthropathy, tophus development, and urolithiasis. Since asymptomatic increased serum urate levels are associated with a higher risk of cardiovascular, renal and metabolic disorders, a larger use of ULTs in the general population is expected in the near future.
New Search Next